Movement Alert｜ImmunityBio Rises 5.06% in Regular Trading, ASCO Clinical Data and Guideline Inclusion Fuel Rebound

Market Focus06-09

On June 9, ImmunityBio rose 5.06% in regular trading, trading at $7.2777/share, with trading volume of $47.51 million. The stock had pulled back since late May on profit-taking after multiple catalysts were priced in, and this rebound appears tied to continued digestion of recent clinical milestones.

On the news front, the company recently presented two posters and one online abstract at the ASCO annual meeting, showcasing latest Phase III clinical data for its IL-15 receptor agonist immunotherapy ANKTIVA in non-small cell lung cancer and bladder cancer. Additionally, INBRX-106 reported mid-Phase II data in first-line head and neck squamous cell carcinoma, with the combination arm achieving a confirmed objective response rate of 44.0% among 25 patients versus 21.4% among 28 patients in the control arm. Furthermore, the CSCO Urothelial Carcinoma Treatment Guidelines have incorporated ANKTIVA combined with BCG as a novel bladder-sparing treatment option, reinforcing its commercial outlook for patients who have failed standard therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116013009?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-09 00:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116013009","market":"hk","top_or_hot":-1,"title":"Movement Alert｜ImmunityBio Rises 5.06% in Regular Trading, ASCO Clinical Data and Guideline Inclusion Fuel Rebound","media":"Market Focus","content":"<p><p>On June 9, ImmunityBio rose 5.06% in regular trading, trading at $7.2777/share, with trading volume of $47.51 million. The stock had pulled back since late May on profit-taking after multiple catalysts were priced in, and this rebound appears tied to continued digestion of recent clinical milestones.</p><p>On the news front, the company recently presented two posters and one online abstract at the ASCO annual meeting, showcasing latest Phase III clinical data for its IL-15 receptor agonist immunotherapy ANKTIVA in non-small cell lung cancer and bladder cancer. Additionally, INBRX-106 reported mid-Phase II data in first-line head and neck squamous cell carcinoma, with the combination arm achieving a confirmed objective response rate of 44.0% among 25 patients versus 21.4% among 28 patients in the control arm. Furthermore, the CSCO Urothelial Carcinoma Treatment Guidelines have incorporated ANKTIVA combined with BCG as a novel bladder-sparing treatment option, reinforcing its commercial outlook for patients who have failed standard therapy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ImmunityBio Rises 5.06% in Regular Trading, ASCO Clinical Data and Guideline Inclusion Fuel Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ImmunityBio Rises 5.06% in Regular Trading, ASCO Clinical Data and Guideline Inclusion Fuel Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-09 00:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 9, ImmunityBio rose 5.06% in regular trading, trading at $7.2777/share, with trading volume of $47.51 million. The stock had pulled back since late May on profit-taking after multiple catalysts were priced in, and this rebound appears tied to continued digestion of recent clinical milestones.</p><p>On the news front, the company recently presented two posters and one online abstract at the ASCO annual meeting, showcasing latest Phase III clinical data for its IL-15 receptor agonist immunotherapy ANKTIVA in non-small cell lung cancer and bladder cancer. Additionally, INBRX-106 reported mid-Phase II data in first-line head and neck squamous cell carcinoma, with the combination arm achieving a confirmed objective response rate of 44.0% among 25 patients versus 21.4% among 28 patients in the control arm. Furthermore, the CSCO Urothelial Carcinoma Treatment Guidelines have incorporated ANKTIVA combined with BCG as a novel bladder-sparing treatment option, reinforcing its commercial outlook for patients who have failed standard therapy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1116013009","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116013009","pubTimestamp":1780937053,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 9, ImmunityBio rose 5.06% in regular trading, trading at $7.2777/share, with trading volume of $47.51 million. The stock had pulled back since late May on profit-taking after multiple...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"动向提示|ImmunityBio常规交易涨5.06%ASCO临床数据和指南纳入助推反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"On June 9, ImmunityBio rose 5.06% in regular trading, trading at $7.2777/share, with trading volume of $47.51 million. The stock had pulled back since late May on profit-taking after multiple catalysts were priced in, and this rebound appears tied to continued digestion of recent clinical milestones.On the news front, the company recently presented two posters and one online abstract at the ASCO annual meeting, showcasing latest Phase III clinical data for its IL-15 receptor agonist immunotherapy ANKTIVA in non-small cell lung cancer and bladder cancer. Additionally, INBRX-106 reported mid-Phase II data in first-line head and neck squamous cell carcinoma, with the combination arm achieving a confirmed objective response rate of 44.0% among 25 patients versus 21.4% among 28 patients in the control arm. Furthermore, the CSCO Urothelial Carcinoma Treatment Guidelines have incorporated ANKTIVA combined with BCG as a novel bladder-sparing treatment option, reinforcing its commercial outlook for patients who have failed standard therapy.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116013009","isCrawlerRequest":true}